What is Pharmatech Associates?
Pharmatech Associates, Inc. operates as a premier consultancy specializing in Chemistry, Manufacturing, and Controls (CMC), quality assurance, and regulatory affairs. The firm provides comprehensive support for the development of biologics, cell and gene therapies, combination products, and small molecules. By offering services that span from facilities design to continuous manufacturing and regulatory submission strategy, the company enables its clients to streamline the path to market approval. Their market position is defined by a deep technical proficiency that helps pharmaceutical and biotechnology companies mitigate risk, enhance product quality, and ensure adherence to rigorous US and international regulatory standards.
How much funding has Pharmatech Associates raised?
Pharmatech Associates has raised a total of $1.1M across 2 funding rounds:
Debt
$350K
Debt
$765K
Debt (2020): $350K with participation from PPP
Debt (2021): $765K led by PPP
Key Investors in Pharmatech Associates
PPP
Public-Private Partnership
What's next for Pharmatech Associates?
With the recent influx of capital, Pharmatech Associates is well-positioned to expand its footprint in the rapidly evolving biologics and advanced therapy medicinal products (ATMP) sectors. The strategic deployment of these funds will likely focus on scaling their regulatory affairs division and enhancing their technical consulting capabilities to meet the surging demand for cell and gene therapy development support. As the industry shifts toward more personalized medicine and complex manufacturing processes, the firm is expected to leverage its financial stability to invest in proprietary compliance frameworks and talent acquisition, further cementing its status as a leader in the pharmaceutical services market. Future growth will likely be driven by the increasing necessity for specialized external expertise as smaller biotech firms continue to dominate the innovation pipeline.
See full Pharmatech Associates company page
